The high antitumor activity of MLN8237 through disruption of mitotic progression (Hoar et al., 2007; Nováková et al., 2017) can provide significant advantages as a drug for the development of the anti-PSMA 5D3-based ADC that targets PSMA (+) PC cells. This evidence concerns the gene FOLH1 and pachyonychia congenita.